[1]熊丽娇,陈丽莉,蔡霞,等.西格列汀对高糖环境下胎鼠海马神经元的影响[J].国际内分泌代谢杂志,2021,41(06):617-622.[doi:10.3760/cma.j.cn121383-20200602-06003]
　Xiong Lijiao,Chen Lili,Cai Xia,et al.Effects of sitagliptin on hippocampal neuronal apoptosis in high glucose environment[J].International Journal of Endocrinology and Metabolism,2021,41(06):617-622.[doi:10.3760/cma.j.cn121383-20200602-06003]
点击复制

西格列汀对高糖环境下胎鼠海马神经元的影响()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
41
期数:
2021年06期
页码:
617-622
栏目:
论著
出版日期:
2021-12-20

文章信息/Info

Title:
Effects of sitagliptin on hippocampal neuronal apoptosis in high glucose environment
作者:
熊丽娇1; 2; 陈丽莉1; 蔡霞3; 邹玲婷1; 万绍媛1; 王萍1; 许荣1; 曾治平1; 2
1赣南医学院第一附属医院,赣州 341000; 2国家老年疾病临床医学研究中心江西分中心,赣州 341000; 3赣南卫生健康职业学院,赣州 341000
Author(s):
Xiong Lijiao1; 2;  Chen Lili1;  Cai Xia3;  Zou Lingting1;  Wan Shaoyuan1;  Wang Ping1;  Xu Rong1;  Zeng Zhiping1; 2.
1The First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, China; 2Jiangxi Branch Center of National Geriatric Disease Clinical Medical Research Center, Ganzhou 341000, China; 3Gannan Healthcare Vocationa
关键词:
西格列汀;  糖尿病;  海马神经元;  细胞凋亡;  氧化应激
Keywords:
Sitagliptin;  Diabetes;  Hippocampal neurons;  Apoptosis;  Oxidative stress
DOI:
10.3760/cma.j.cn121383-20200602-06003
摘要:
目的 观察西格列汀对高糖环境下胎鼠海马神经元的影响。方法 原代胎鼠海马神经元细胞培养7 d,分为对照组(Con组)、高糖模型组(Mod组)、西格列汀组(Sita组)和甘露醇组(MT组)。Con组不处理,Sita组及Mod组使用高糖环境(100 mmol/L),Sita组加入100 μmol/L西格列汀,MT组加入4.5%甘露醇,处理24 h。应用噻唑蓝(MTT)法测细胞活力,原位末端转移酶标记技术(TUNEL)染色及膜连蛋白V/碘化丙啶(AnnexinV-FITC/PI)流式细胞术测细胞凋亡,蛋白质免疫印迹技术测定B细胞淋巴瘤/白血病-2基因(Bcl-2)、Bcl-2相关X蛋白基因蛋白(Bax)、含半胱氨酸的天冬氨酸蛋白水解酶-3(Caspase-3)的表达,测定丙二醛(MDA)含量及超氧化物歧化酶(SOD)活性。结果 MT组存活率、凋亡率、MDA、SOD及各蛋白表达与对照组比差异无统计学意义(P>0.05)。Mod组较Con组海马神经元细胞存活率下降(P<0.05),凋亡率升高(P<0.05),Bax、Caspase-3表达和MDA含量增加(P均<0.05),Bcl-2表达和SOD活力降低(P均<0.05)。Sita组较Mod组存活率上升(P<0.05),凋亡率下降(P<0.05),Caspase-3、Bax表达和MDA含量降低(P<0.05),Bcl-2表达和SOD活力增加(P均<0.05)。结论 在细胞水平西格列汀可抑制高糖环境下海马神经元细胞凋亡和氧化应激,具有神经保护作用。
Abstract:
Objective To observe the effects of sitagliptin on hippocampal neurons in fetal rats under a high glucose environment.Methods Primary fetal hippocampal neurons were cultured for 7 days and divided into control group(Con group), high glucose model group(Mod group), sitagliptin group(Sita group)and mannitol group(MT group). The Con group was not treated. The Sita group and the Mod group were treated with high glucose(100 mmol/L). The Sita group was treated with 100 μmol/L sitagliptin. MT group was treated with 4.5% mannitol. All of them were treated for 24 h. Cell viability was measured by methyl thiazolyl tetrazolium(MTT)method, and apoptosis rate was measured by Terminal-deoxynucleoitidyl Transferase Mediated Nick End Labeling(TUNEL)staining and AnnexinV-FITC/PI flow cytometry. B-cell lymphocyte/leukemia-2(Bcl-2), Bcl-2 associated X protein gene protein(Bax), and Caspase-3 protein expression were measured by Western-blot method. Malondialdehyde(MDA)content and superoxide dismutase(SOD)activity were measured.Results There were no significant differences in apoptosis rate, MDA, SOD and protein expression between MT group and Con group(all P>0.05). Compared with Con group, the cell viability of hippocampal neurons in Mod group was decreased(P<0.05)and the apoptosis rate was increased(P<0.05). Caspase-3, Bax expression and MDA content in Mod group were increased compared with Con group(all P<0.05), and the expressions of Bcl-2 and SOD activity were decreased(all P<0.05). The survival rate of Sita group was higher than that of Mod group(all P<0.05), and the apoptosis rate was lower(P<0.05). Caspase-3, Bax expression and MDA content in Sita group were significantly lower than those in Mod group(P<0.05). In contrast, Bcl-2 expression and SOD activity expressions were substantially higher than those in Mod group(all P<0.05).Conclusion Sitagliptin could play a neuroprotective role by inhibiting apoptosis and oxidative stress in hippocampal neurons under high glucose environment at the cellular level.

参考文献/References:

[1] Xue J,Wang C,Pan C,et al.Effect of DPP-4 inhibitor on elderly patients with T2DM combined with MCI[J].Exp Ther Med,2020,19(2):1356-1362.DOI:10.3892/etm.2019.8339.
[2] Wang Q,Wang D,Cheng A,et al.Comparison between the effects of sitagliptin and liraglutide on blood glucose and cognitive function of patients with both type 2 diabetes mellitus and post-stroke mild cognitive impairment[J].Int J Clin Exp Med,2020,13(2):1219-1227.WOS:000518397600109.
[3] Campos EJ,Martins J,Brudzewsky D,et al.Neuropeptide Y system mRNA expression changes in the hippocampus of a type Ⅰ diabetes rat model[J].Ann Anat,2020,227:151419.DOI:10.1016/j.aanat.2019.151419.
[4] Cao B,Rosenblat JD,Brietzke E,et al.Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment:a systematic review and network meta-analysis[J].Diabetes Obes Metab.2018,20(10):2467-2471.DOI:10.1111/dom.13373.
[5] Isik AT,Soysal P,Yay A,et al.The effects of sitagliptin,a DPP-4 inhibitor,on cognitive functions in elderly diabetic patients with or without Alzheimer's disease[J].Diabetes Res Clin Pract,2017,123:192-198.DOI:10.1016/j.diabres.2016.12.010.
[6] Kumar S,Chowdhury S,Razdan A,et al.Downregulation of candidate gene expression and neuroprotection by piperine in streptozotocin-induced hyperglycemia and memory impairment in rats[J].Front Pharmacol,2021,11:595471.DOI:10.3389/fphar.2020.595471.
[7] Bernstein HG,Dobrowolny H,Keilhoff G,et al.Dipeptidyl peptidase Ⅳ,which probably plays important roles in Alzheimer disease(AD)pathology,is upregulated in AD brain neurons and associates with amyloid plaques[J].Neurochem Int,2018,114:55-57.DOI:10.1016/j.neuint.2018.01.005.
[8] Li J,Zhang S,Li C,et al.Sitagliptin rescues memory deficits in Parkinsonian rats via upregulating BDNF to prevent neuron and dendritic spine loss[J].Neurol Res,2018,40(9):736-743.DOI:10.1080/01616412.2018.1474840.
[9] Badawi GA,Abd El Fattah MA,Zaki HF,et al.Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson's disease[J].Inflammopharmacology,2017,25(3):369-382.DOI:10.1007/s10787-017-0331-6.
[10] Safar MM,Shahin NN,Mohamed AF,et al.Suppression of BACE1 and amyloidogenic/RAGE axis by sitagliptin ameliorates PTZ kindling-induced cognitive deficits in rats[J].Chem Biol Interact,2020,328:109144.DOI:10.1016/j.cbi.2020.109144.
[11] Zhang Y,Liu Y,Xu J,et al.Inhibition of DPP4 enhances inhibitory synaptic transmission through activating the GLP-1/GLP-1R signaling pathway in a rat model of febrile seizures[J].Biochem Pharmacol,2018,156:78-85.DOI:10.1016/j.bcp.2018.08.004.
[12] Nader MA,Ateyya H,El-Shafey M,et al.Sitagliptin enhances the neuroprotective effect of pregabalin against pentylenetetrazole-induced acute epileptogenesis in mice:implication of oxidative,inflammatory,apoptotic and autophagy pathways[J].Neurochem Int,2018,115:11-23.DOI:10.1016/j.neuint.2017.10.006.
[13] Li Y,Tian Q,Li Z,et al.Activation of Nrf2 signaling by sitagliptin and quercetin combination against β-amyloid induced Alzheimer's disease in rats [J].Drug Dev Res,2019,80(6):837-845.DOI:10.1002/ddr.21567.
[14] Ibrahim MA,Geddawy A,Abdel-Wahab S.Sitagliptin prevents isoproterenol-induced myocardial infarction in rats by modulating nitric oxide synthase enzymes[J].Eur J Pharmacol,2018,829:63-69.DOI:10.1016/j.ejphar.2018.04.005.
[15] Tsai T,Sun C,Su C,et al.Sitagliptin attenuated brain damage and cognitive impairment in mice with chronic cerebral hypo-perfusion through suppressing oxidative stress and inflammatory reaction[J].J Hypertens,2015,33(5):1001-1013.DOI:10.1097/HJH.0000000000000529.
[16] Han W,Li Y,Cheng J,et al.Sitagliptin improves functional recovery via GLP-1R-induced anti-apoptosis and facilitation of axonal regeneration after spinal cord injury[J].J Cell Mol Med,2020,24(15):8687-8702.DOI:10.111/jcmm.15501.

相似文献/References:

[1]李春睿,王静,陈峰,等.GLP-1受体激动剂对糖尿病患者肾功能的影响[J].国际内分泌代谢杂志,2014,(06):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
　Li Chunrui*,Wang Jing,Chen Feng,et al.Effects of GLP-1 receptor agonists on renal function of diabetics[J].International Journal of Endocrinology and Metabolism,2014,(06):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
[2]黄珊珊,鲁一兵.长链非编码RNA与糖尿病[J].国际内分泌代谢杂志,2015,(04):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
　Huang Shanshan*,Lu Yibing..Long non-coding RNA and diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(06):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
[3]高瑞霄,姚朱华,冯凭,等.尿8-羟基脱氧鸟苷在2型糖尿病及糖尿病合并冠心病患者中的临床意义[J].国际内分泌代谢杂志,2014,(05):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
　Gao Ruixiao*,Yao Zhuhua,Feng Ping,et al.The clinical significance of urinary 8-hydroxy deoxyguanosine in patients with type 2 diabetes mellitus and diabetic patients with coronary heart disease[J].International Journal of Endocrinology and Metabolism,2014,(06):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
[4]郑佳,肖新华.葡萄糖稳态的中枢调控作用机制 ——2014年美国糖尿病协会“杰出科学成就奖” 演讲报告解读[J].国际内分泌代谢杂志,2014,(05):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
　Zheng Jia,Xiao Xinhua.The mechanisms of central nervous system in the control of glucose homeostasis--A summary of 2014 ADA "Outstanding Scientific Achievement Award" Lecture[J].International Journal of Endocrinology and Metabolism,2014,(06):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
[5]唐勤,邵莉.蛋白乙酰化与胰岛素分泌[J].国际内分泌代谢杂志,2014,(05):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
　Tang Qin,Shao Li..Protein acetylation and insulin secretion[J].International Journal of Endocrinology and Metabolism,2014,(06):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
[6]卢婷婷,任思佳,沈捷.人群迁徙对糖尿病患病率的影响及其相关因素[J].国际内分泌代谢杂志,2014,(05):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
　Lu Tingting,Ren Sijia,Shen Jie..Impact of migration on prevalence of diabetes and risk factors[J].International Journal of Endocrinology and Metabolism,2014,(06):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
[7]包薇萍,陈国芳,刘超.DPP-4抑制剂的肾保护作用[J].国际内分泌代谢杂志,2014,(05):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
　Bao Weiping,Chen Guofang,Liu Chao..Renal protective effects of dipeptidyl peptidase-4 inhibitors[J].International Journal of Endocrinology and Metabolism,2014,(06):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
[8]孟庆冬,陶红.巨噬细胞凋亡与糖尿病动脉粥样硬化[J].国际内分泌代谢杂志,2014,(05):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
　Meng Qingdong,Tao Hong..Macrophage apoptosis and diabetic atherosclerosis[J].International Journal of Endocrinology and Metabolism,2014,(06):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
[9]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
　Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(06):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[10]吕丹 李晓思 陈树春 王泽普.Betatrophin:糖尿病再生治疗的新希望[J].国际内分泌代谢杂志,2015,(05):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]
　Lyu Dan*,Li Xiaosi,Chen Shuchun,et al.Betatrophin:new hope for regeneration therapy of diabetes[J].International Journal of Endocrinology and Metabolism,2015,(06):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]

备注/Memo

备注/Memo:
基金项目:江西省教育厅科技项目(GJJ201545); 赣南医学院科研课题(YB201808); 赣州市指导性科技计划(GZ2018ZSF010); 赣南医学院第一附属医院院级科技计划(YJZD202011)
通信作者:陈丽莉, Email:c15179718189@163.com
更新日期/Last Update: 2021-12-10